SRL and breast cancer: It will be also worth reassessing the clinical outcome of two recent large phase III trials of adjuvant denosumab in early BC, D-CARE, and ABCSG-18, according to the predictive biomarkers we defined as follows: baseline RANK metagene, sRL levels, and the presence of Tregs.